PF-Atlas › Clinical Trials › NCT07728721

Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

HSK50042 dose 1 · Phase 2

Registry ID
NCT07728721
Phase
Phase 2
Status
Not yet recruiting
Drug / intervention
HSK50042 dose 1
Sponsor
Haisco Pharmaceutical Group Co., Ltd.
Enrollment
175

About this trial

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

View NCT07728721 on ClinicalTrials.gov →

Explore related

All HSK50042 dose 1 trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT07728721 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.